

# Eun Sung Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8694253/publications.pdf>

Version: 2024-02-01

20  
papers

5,218  
citations

471061

17  
h-index

752256

20  
g-index

28  
all docs

28  
docs citations

28  
times ranked

8839  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
2	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 383-391.	15.2	65
3	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
4	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
5	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
6	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. <i>Structure</i> , 2022, 30, 1233-1244.e7.	1.6	13
7	Broadly neutralizing antibodies target the coronavirus fusion peptide. <i>Science</i> , 2022, 377, 728-735.	6.0	111
8	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
9	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
10	Blocking $\alpha 4 \beta 7$ integrin delays viral rebound in SHIV $\Delta$ SF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	11
11	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
12	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
13	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	6.0	244
14	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101127.	1.6	9
15	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
16	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	13.7	1,153
17	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
18	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. <i>Scientific Reports</i> , 2020, 10, 18149.	1.6	90

#	ARTICLE	IF	CITATIONS
19	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	6.0	348
20	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016, 166, 609-623.	13.5	270